Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response
Top Cited Papers
- 1 July 2011
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 10 (7), 495-506
- https://doi.org/10.1038/nrd3501
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- e‐SPC – delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribersBritish Journal of Clinical Pharmacology, 2011
- Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trialThe Lancet, 2010
- EBM, HTA, and CER: Clearing the ConfusionThe Milbank Quarterly, 2010
- Fruit juice inhibition of uptake transport: a new type of food–drug interactionBritish Journal of Clinical Pharmacology, 2010
- Pharmacogenomics: a new paradigm to personalize treatments in nephrology patientsClinical and Experimental Immunology, 2009
- Proposals for model‐based paediatric medicinal development within the current European Union regulatory frameworkBritish Journal of Clinical Pharmacology, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a reviewInternational Journal of Clinical Practice, 2007
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006
- Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problemsStatistics in Medicine, 2002